Is vancomycin MIC creep a worldwide phenomenon? Assessment of S. aureus vancomycin MIC in a tertiary university hospital

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Joana, Silvestre ^a,b   Pedro, Póvoa ^a,b   Elsa, Gonçalves ^a   Filomena, Martins ^a  

^a HOSPITAL DE SÃO FRANCISCO XAVIER   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

ANTIINFECTIVE AGENT; VANCOMYCIN;

ARTICLE; DRUG EFFECT; HUMAN; MICROBIAL SENSITIVITY TEST; STAPHYLOCOCCUS AUREUS; UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

MLCS; MLOWN;

EID: 84873940874     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-65     Document Type: Article

References (23)

1. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Styers D, Sheehan DJ, Hogan P, Sahm DF, Ann Clin Microbiol Antimicrob 2006 5 2 10.1186/1476-0711-5-2 16469106 (Pubitemid 43379400)
2. Methicillin-resistant Staphylococcus aureus: the European landscape. Johnson AP, J Antimicrob Chemother 66 Suppl 4 v43 iv48
3. European Centre for Disease Prevention and Control, Antimicrobial resistance surveillance in Europe 2010. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) Stockholm: ECDC 2011
4. Estudo multice ntrico de resiste ncia aos antimicrobianos em nove hospitais portugueses. Comparac a o de resultados num intervalo de uma de cada. Melo-Cristino JAAF, Amorim JM, Diogo J, Lito LM, Lopes P, Marques J, Marques T, Martins F, Monteiro L, Nascimento I, Pessanha MA, Piedade J, Ramos MH, Ribeiro G, Rodrigues A, Salgado MJ, Sobral L, Spencer D, Revista Portuguesa de Doenc as Infecciosas 2006 3 7 15 23410591
5. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Jones RN, Clin Infect Dis 2006 42 Suppl 1 13 S24 16323115
6. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Liu C, Bayer A, Cosgrove SE, et al. Clin Infect Dis 2011 52 285 92 10.1093/cid/cir034 21217178
7. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Maclayton DO, Suda KJ, Coval KA, York CB, Garey KW, Clin Ther 2006 28 1208 1216 10.1016/j.clinthera.2006.08.003 16982298 (Pubitemid 44374748)
8. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Moise-Broder PA, Sakoulas G, Eliopoulos GM, Schentag JJ, Forrest A, Moellering RC Jr, Clin Infect Dis 2004 38 1700 1705 10.1086/421092 15227615 (Pubitemid 38781661)
9. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM, J Clin Microbiol 2004 42 2398 2402 10.1128/JCM.42.6.2398-2402.2004 15184410 (Pubitemid 38747480)
10. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Shorr AF, Combes A, Kollef MH, Chastre J, Crit Care Med 2006 34 700 706 10.1097/01.CCM.0000201885.57697.21 16505656
11. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Tverdek FP, Crank CW, Segreti J, Crit Care Clin 2008 24 249 260 vii-viii 10.1016/j.ccc.2007.12.013 18361944 (Pubitemid 351419194)
12. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. Alos JI, Garcia-Canas A, Garcia-Hierro P, Rodriguez-Salvanes F, J Antimicrob Chemother 2008 62 773 775 10.1093/jac/dkn246 18552338
13. Vancomycin MIC creep in MRSA isolates from 1997 to 2008 in a healthcare region in Hong Kong. Ho PL, Lo PY, Chow KH, Lau EH, Lai EL, Cheng VC, Kao RY, J Infect 2010 60 2 140 145 10.1016/j.jinf.2009.11.011 19961873
14. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. Steinkraus G, White R, Vancomycin FL, J Antimicrob Chemother 2007 60 788 794 10.1093/jac/dkm258 17623693 (Pubitemid 47434257)
15. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Appelbaum PC, Int J Antimicrob Agents 2007 30 398 408 10.1016/j.ijantimicag.2007.07.011 17888634 (Pubitemid 47498971)
16. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A, Arch Intern Med 2006 166 2138 2144 10.1001/archinte.166.19. 2138 17060545 (Pubitemid 44631403)
17. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Lodise TP, Graves J, Evans A, et al. Antimicrob Agents Chemother 2008 52 3315 3320 10.1128/AAC.00113-08 18591266
18. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Moise PA, Sakoulas G, Forrest A, Schentag JJ, Antimicrob Agents Chemother 2007 51 2582 2586 10.1128/AAC.00939-06 17452488 (Pubitemid 47047340)
19. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Soriano A, Marco F, Martinez JA, et al. Clin Infect Dis 2008 46 193 200 10.1086/524667 18171250 (Pubitemid 351269157)
20. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Choi EY, Huh JW, Lim CM, Koh Y, Kim SH, Choi SH, Kim YS, Kim MN, Hong SB, Intensive Care Med 2010 37 4 639 647
21. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Sader HS, Rhomberg PR, Jones RN, Antimicrob Agents Chemother 2009 53 3162 3165 10.1128/AAC.00093-09 19398641
22. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Prakash V, Lewis JS 2nd, Jorgensen JH, Antimicrob Agents Chemother 2008 52 4528 10.1128/AAC.00904-08 18838599
23. Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. Leonard SN, Rossi KL, Newton KL, Rybak MJ, J Antimicrob Chemother 2009 63 489 492 10.1093/jac/dkn520 19136530